Skip to Content

Stroke Program Clinical Trials

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial
Aims: To determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg of clopidogrel is effective in preventing major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours of transient ischemic attack (TIA) or minor ischemic stroke onset in patients receiving aspirin 50-325 mg/day (with a dose of 162 mg daily for 5 days followed by 81 mg daily strongly recommended).
Principal Investigator: Archie Ong, MD
NorthShore Project Number: EH11-057
Funding source: The National Institute of Neurological Disorders and Stroke (NINDS)
Contact: Please call 847.503.4322 with questions regarding the study
Open to enrollment: Yes

ENRICH: Early Minimally-Invasive Removal of ICH
The purpose of this study is to provide clinical evidence of functional improvement, safety, and economic benefit when comparing intracerebral hemorrhage (ICH) evacuation (removal of a blood clot from the brain using the minimally invasive BrainPath access system), to medical treatment.
Principal Investigator: Shakeel Chowdhry, MD
NorthShore Project Number: EH17-038
Contact: Call 847.570.4224 with questions regarding the study
Open to enrollment: Yes